Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
Hypersensitivity to pegaspargase is associated with inferior survival in pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. In the past year, drug-supply shortages have led to the lack of an available alternative to pegaspargase. Rather than omit asparaginase from the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma patients with hypersensitivity to pegaspargase, we continued pegaspargase treatments for nine pediatric patients, utilizing a rapid desensitization protocol. There were no adverse events related to the pegaspargase during desensitization, and all patients who were checked had asparaginase serum levels above the threshold of 0.1 IU/mL at 7 to 14 days after pegaspargase therapy.
Pediatric blood & cancer
Adolescent; Antineoplastic Agents; Asparaginase; Desensitization, Immunologic; Humans; Lymphoma, T-Cell; Male; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis
acute lymphoblastic leukemia; asparaginase; children; lymphoblastic lymphoma
August, K. J., Farooki, S., Fulbright, J. M., August, A., Portnoy, J. M., Pommert, L., Burke, M. J., Guest, E. M. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Pediatric blood & cancer 67, (2020).